Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Shanghai,china-dec.28th,2023:,Soleno,Therapeutics,Company,Brand,Logo,On,Official,Website

Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).

Vykat XR, a modified tablet version of a 50-year-old generic suspension, carries an annual cost of $500,000, the report claims.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.